Equities analysts expect iRhythm Technologies, Inc. (NASDAQ:IRTC) to post ($1.09) earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for iRhythm Technologies’ earnings, with the highest EPS estimate coming in at ($1.02) and the lowest estimate coming in at ($1.19). iRhythm Technologies reported earnings of ($0.17) per share during the same quarter last year, which suggests a negative year over year growth rate of 541.2%. The business is expected to report its next quarterly earnings report on Thursday, November 4th.
On average, analysts expect that iRhythm Technologies will report full-year earnings of ($3.66) per share for the current year, with EPS estimates ranging from ($3.81) to ($3.53). For the next fiscal year, analysts forecast that the firm will post earnings of ($3.50) per share, with EPS estimates ranging from ($4.55) to ($2.30). Zacks’ EPS calculations are an average based on a survey of sell-side research analysts that follow iRhythm Technologies.
iRhythm Technologies (NASDAQ:IRTC) last announced its earnings results on Thursday, August 5th. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.38. The business had revenue of $81.28 million during the quarter, compared to analysts’ expectations of $72.95 million. iRhythm Technologies had a negative net margin of 19.41% and a negative return on equity of 18.41%.
IRTC traded up $0.78 on Monday, hitting $59.19. 7,034 shares of the company were exchanged, compared to its average volume of 625,146. The business’s fifty day moving average is $51.06 and its 200 day moving average is $74.22. The firm has a market capitalization of $1.74 billion, a P/E ratio of -28.56 and a beta of 1.43. iRhythm Technologies has a fifty-two week low of $41.66 and a fifty-two week high of $286.19. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.47 and a current ratio of 4.60.
Hedge funds have recently modified their holdings of the company. Blair William & Co. IL raised its stake in shares of iRhythm Technologies by 134.3% in the 1st quarter. Blair William & Co. IL now owns 498,163 shares of the company’s stock valued at $69,175,000 after acquiring an additional 285,555 shares during the period. Nomura Holdings Inc. acquired a new stake in iRhythm Technologies during the 1st quarter valued at $904,000. US Bancorp DE grew its holdings in iRhythm Technologies by 69.5% during the 2nd quarter. US Bancorp DE now owns 2,356 shares of the company’s stock valued at $156,000 after purchasing an additional 966 shares in the last quarter. Squarepoint Ops LLC grew its holdings in iRhythm Technologies by 1,540.0% during the 1st quarter. Squarepoint Ops LLC now owns 67,353 shares of the company’s stock valued at $9,353,000 after purchasing an additional 63,246 shares in the last quarter. Finally, Swiss National Bank grew its holdings in iRhythm Technologies by 1.9% during the 1st quarter. Swiss National Bank now owns 66,000 shares of the company’s stock valued at $9,165,000 after purchasing an additional 1,200 shares in the last quarter. 96.92% of the stock is currently owned by institutional investors and hedge funds.
About iRhythm Technologies
iRhythm Technologies, Inc engages in the development of monitoring and diagnostic solutions for detection of cardiac arrhythmias. It offers Zio XT, is a wearable patch-based biosensor, continuously records, and stores ECG data from every patient heartbeat for up to 14 consecutive days; and Zio AT, also provides ECG data but also provides physicians with actionable notifications during the wear period.
Recommended Story: How is the S&P 500 index different from the DJIA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for iRhythm Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iRhythm Technologies and related companies with MarketBeat.com's FREE daily email newsletter.